Jorg M. Mezger
Karlsruhe, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Pharmacotherapy in the climate crisis: Practical implications for patient care
Journal: MMW Fortschritte der Medizin
Published: July 10, 2025
Experimental Observation of the Motion of Ions in a Resonantly Driven Plasma Wakefield Accelerator.
Journal: Physical review letters
Published: June 25, 2024
NCCN guideline-concordant cancer care in sub-Saharan Africa: a population-based multicountry study of 5 cancers.
Journal: Journal of the National Cancer Institute
Published: April 09, 2024
Guideline Concordance of Treatment and Outcomes Among Adult Non-Hodgkin Lymphoma Patients in Sub-Saharan Africa: A Multinational, Population-Based Cohort.
Journal: The oncologist
Published: August 05, 2022
Clinical presentation and diagnosis of adult patients with non-Hodgkin lymphoma in Sub-Saharan Africa.
Journal: British journal of haematology
Published: December 16, 2019
Very Severe Differentiation Syndrome in Low Risk Acute Promyelocytic Leukemia - A Peril of Differentiating Therapy
Journal: Deutsche medizinische Wochenschrift (1946)
Published: January 24, 2017
Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.
Journal: British journal of cancer
Published: May 31, 2016
Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE).
Journal: Oncology research and treatment
Published: May 03, 2016
Exemption: Promyelocytic Leukemia.
Journal: Deutsches Arzteblatt international
Published: August 08, 2015
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Journal: The Lancet. Oncology
Published: February 22, 2015
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Journal: Lancet (London, England)
Published: December 26, 2014
Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: December 02, 2014
Last Updated: 09/26/2026